Vaxart COVID-19 vaccine is a COVID-19 vaccine candidate developed by Vaxart.[2][3][4]
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Other names | VXA-CoV2-1, VXA-CoV2-1.1-S |
| Routes of administration | Oral |
| Identifiers | |
| CAS Number | |
References
edit- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ Clinical trial number NCT04563702 for "Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults" at ClinicalTrials.gov
- ^ Clinical trial number NCT05067933 for "Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine (VXA-NVV-104)" at ClinicalTrials.gov
- ^ Clinical trial number NCT05067933 for "A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine" at ClinicalTrials.gov
Scholia has a profile for Vaxart COVID-19 vaccine (Q110269782).
.svg){kind=small}